Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rPA vaccine + alhydrogel
- Development stage
- Unknown
- Lead developer
- Avecia Biologics
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The rPA vaccine + alhydrogel is a combination anthrax subunit vaccine composed of recombinant Protective Antigen (rPA or rPA83), a protein component of *Bacillus anthracis* toxin, and the aluminum hydroxide-based adjuvant Alhydrogel. The recombinant PA is typically produced in *Escherichia coli* and purified for use. Alhydrogel acts as an immunologic adjuvant by forming a depot at the injection site and enhancing immune responses through increased antigen availability and activation of innate immunity pathways such as the NLRP3 inflammasome. The combination has demonstrated safety and immunogenicity in humans and provides protection against anthrax in animal models[1][2][5]. This formulation is under development primarily for prophylaxis against inhalational anthrax.
- Other names
- anthrax sub-unit vaccine (rPA83/Alhydrogel)recombinant protective antigen (rPA) adsorbed to AlhydrogelrPA-AlOH formulation
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on rPA vaccine + alhydrogel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rPA vaccine + alhydrogel.